SCHEMBL215461

SCHEMBL215461

Cc1cc(C(=O)O)c(O)c(C(C)(C)C)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.63
CA2 P00918 2/20 0.63
ALDH1A1 P00352 2/20 0.63
POLB P06746 1/20 0.63
TYR P14679 1/20 0.63
GLRA3 O75311 1/20 0.55
GLRB P48167 1/20 0.55
HSPA5 P11021 1/20 0.52
CYP2C9 P11712 3/20 0.50
CYP2C19 P33261 3/20 0.50
HIF1A Q16665 2/20 0.50
CSNK2A1 P68400 1/20 0.46
CYP2D6 P10635 1/20 0.45
HSD17B10 Q99714 1/20 0.45
KDM4E B2RXH2 1/20 0.44
CA1 P00915 1/20 0.43
PTGS1 P23219 1/20 0.43
PTGS2 P35354 1/20 0.43
CYP1A2 P05177 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29623812 1.00 SMN1; SMN2 (0.63) SMN1; SMN2CA2ALDH1A1POLBTYR
SCHEMBL11773023 0.98 SMN1; SMN2 (0.61) SMN1; SMN2CA2ALDH1A1POLBTYR
SCHEMBL7198879 0.86 SMN1; SMN2 (0.65) SMN1; SMN2CA2ALDH1A1POLBTYR
SCHEMBL17500078 0.85 SMN1; SMN2 (0.63) SMN1; SMN2CA2ALDH1A1POLBTYR
SCHEMBL7636127 0.85 SMN1; SMN2 (0.63) SMN1; SMN2CA2ALDH1A1POLBTYR
SCHEMBL25564616 0.83 CSNK2A1 (0.44) SMN1; SMN2CA2ALDH1A1POLBTYR
SCHEMBL8747786 0.83 SMN1; SMN2 (0.61) SMN1; SMN2CA2ALDH1A1POLBTYR
SCHEMBL39336 0.82 GLRA3 (0.57) SMN1; SMN2CA2ALDH1A1POLBTYR
SCHEMBL28898246 0.82 SMN1; SMN2 (0.55) SMN1; SMN2CA2ALDH1A1POLBTYR
SCHEMBL9250721 0.82 ALDH1A1 (0.41) SMN1; SMN2CA2ALDH1A1POLBTYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144729-A1 A CLEANSING COMPOSITION L'OREAL (FR) 2026-05-28 US claimed
EP-4611719-A1 A CLEANSING COMPOSITION L'OREAL (FR) 2025-09-10 EP claimed
CN-120076784-A Cleaning composition 莱雅公司 2025-05-30 CN claimed
WO-2024092386-A1 A CLEANSING COMPOSITION L'OREAL (FR) 2024-05-10 WO claimed
US-8974804-B2 Composition in the form of an oil-in-water emulsion and uses thereof L'OREAL (FR) 2015-03-10 US claimed
US-20120301414-A1 COMPOSITION IN THE FORM OF AN OIL-IN-WATER EMULSION AND USES THEREOF L'OREAL (FR) 2012-11-29 US claimed
EP-1415645-B1 Composition in the form of an oil-in-water emulsion and its cosmetic uses OREAL (FR) 2007-10-03 EP claimed
US-6835517-B2 Mixture of binder, colorant, charge control agent and wax; electrostatic latent images RICOH COMPANY, LTD. (JP) 2004-12-28 US claimed
US-20040166128-A1 Composition in the form of an oil-in-water emulsion and uses thereof L'OREAL (FR) 2004-08-26 US claimed
US-4910021-A Oral administered coated capsule for colonic absorption R. P. SCHERER CORPORATION (US) 1990-03-20 US claimed
US-4470980-A Method of increasing oral absorption of β-lactam antibiotics INTERX RESEARCH CORP. (US) 1984-09-11 US claimed
US-4464363-A HYDROXY ARYL- OR HYDROXY ARALKYL ACIDS OR SALTS MERCK & CO., INC. (US) 1984-08-07 US claimed
US-4462991-A POLYPEPTIDE ADJUVANTS OF CARBOXY- OR SULFOSUBSTITUTED PHENOLS INTERX RESEARCH CORP. (US) 1984-07-31 US claimed
US-4459295-A Method of increasing oral absorption of glycosidic and related antibiotics INTERX RESEARCH CORPORATION (US) 1984-07-10 US claimed
US-4406896-A ANTIBIOTICS, ACIDS, HYDROXY MERCK & CO., INC. (US) 1983-09-27 US claimed
EP-0036534-A1 An orally administrable drug form comprising a beta-lactam antibiotic and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-30 EP claimed
EP-0036145-A1 An orally administered drug form comprising a polar bioactive agent and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-23 EP claimed
EP-0035770-A2 An orally administered drug form comprising a glycosidic antibiotic and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-16 EP claimed
EP-0031561-A2 A rectally administered suppository comprising a drug and an adjuvant MERCK & CO. INC. (US) 1981-07-08 EP claimed
US-4121013-A 3,5-SUBSTITUTED SALICYLIC ACID, ZINC COMPOUND, AMMONIUM HYDROXIDE, COATINGS, SENSITIZED FOR COLOR DEVELOPMENT NCR CORPORATION (US) 1978-10-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120301414-A1 COMPOSITION IN THE FORM OF AN OIL-IN-WATER EMULSION AND USES THEREOF PLOD3, CUTA, LOXL1 SMN1; SMN2 1549/4885CA2 4668/4885ALDH1A1 1155/4885
US-20040166128-A1 Composition in the form of an oil-in-water emulsion and uses thereof PLOD3, CUTA, LOXL1 SMN1; SMN2 1549/4885CA2 4668/4885ALDH1A1 1155/4885
US-20260144729-A1 A CLEANSING COMPOSITION SMURF1, CUTA, S100B SMN1; SMN2 1451/4885CA2 1445/4885ALDH1A1 780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.